Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($1.02) by $0.24. On average, analysts expect Corbus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Corbus Pharmaceuticals Stock Up 3.6 %

Shares of CRBP stock traded up $0.27 during mid-day trading on Friday, reaching $7.79. The company's stock had a trading volume of 91,583 shares, compared to its average volume of 364,969. The firm has a market capitalization of $95.29 million, a PE ratio of -1.66 and a beta of 3.19. The company's 50 day simple moving average is $6.39 and its 200-day simple moving average is $11.15. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $61.90.

Wall Street Analyst Weigh In

CRBP has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. William Blair assumed coverage on shares of Corbus Pharmaceuticals in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Wedbush reaffirmed an "outperform" rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Jefferies Financial Group decreased their price objective on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Finally, StockNews.com upgraded Corbus Pharmaceuticals to a "sell" rating in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $59.13.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.